Mapi - Pharma (Mapi - Pharma) Interest Expense : $-0.22 Mil (TTM As of Jun. 2015)

View and export this data going back to . Start your Free Trial

What is Mapi - Pharma Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Mapi - Pharma's interest expense for the six months ended in Jun. 2015 was $ -0.22 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2015 was $-0.22 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Mapi - Pharma's Operating Income for the six months ended in Jun. 2015 was $ -2.43 Mil. Mapi - Pharma's Interest Expense for the six months ended in Jun. 2015 was $ -0.22 Mil. Mapi - Pharma did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Mapi - Pharma Interest Expense Historical Data

The historical data trend for Mapi - Pharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mapi - Pharma Interest Expense Chart

Mapi - Pharma Annual Data

Trend

Dec12

Dec13

Dec14

Interest Expense

-0.03

Mapi - Pharma Semi-Annual Data
	Dec12	Dec13	Jun14	Dec14	Jun15
Interest Expense	-	-	-0.02	-	-0.22

Mapi - Pharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2015 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.22 Mil.

Mapi - Pharma (NAS:MAPI) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Mapi - Pharma's Interest Expense for the six months ended in Jun. 2015 was $-0.22 Mil. Its Operating Income for the six months ended in Jun. 2015 was $-2.43 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2015 was $0.00 Mil.

Mapi - Pharma's Interest Coverage for the quarter that ended in Jun. 2015 is calculated as

Mapi - Pharma did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Mapi - Pharma (Mapi - Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mapi - Pharma Ltd (NAS:MAPI) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.mapi-pharma.com

Mapi - Pharma Ltd was incorporated under the laws of the State of Israel on January 29, 2008. It is a development stage pharmaceutical company, engaged in the development of high-barrier to entry and high-added value generic drugs that include complex active pharmaceutical ingredients or APIs, formulations and life cycle management or LCM products that target large markets. The Company is developing two LCM products for the treatment of multiple sclerosis and neuropathic pain. It is also developing a portfolio of approximately 13 complex APIs. Its LCM portfolio focuses on market product, consisting of Glatiramer Acetate Depot, a once-monthly injection for the treatment of MS, Pregabalin ER, extended release capsules for the treatment of neuropathic pain and epilepsy, and Risperidone LAI, a depot formulation of Risperdal Consta, expected to be developed under the abbreviated new drug application ANDA or 505(b)(2) shortened regulatory pathway. Its competitors in the generic pharmaceutical products and LCM markets includes Teva Pharmaceutical Industries Ltd.; Impax Laboratories, Inc.; Alkermes Plc.; Momenta Pharmaceuticals, Inc.; and Andrx Corporation; a private U.S. company. The Company's current patent portfolio contains approximately 20 patent applications for complex APIs, formulations, polymorphs, and routes of synthesis. Its operations are subject to many governmental regulations.